300841 Stock Overview
Chengdu Kanghua Biological Products Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Chengdu Kanghua Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥58.08 |
| 52 Week High | CN¥79.08 |
| 52 Week Low | CN¥44.01 |
| Beta | 2.45 |
| 1 Month Change | -0.55% |
| 3 Month Change | 29.07% |
| 1 Year Change | -16.86% |
| 3 Year Change | -49.26% |
| 5 Year Change | n/a |
| Change since IPO | -81.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300841 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 2.6% | -1.9% | -1.2% |
| 1Y | -16.9% | -16.2% | 11.8% |
Return vs Industry: 300841 matched the CN Biotechs industry which returned -17.6% over the past year.
Return vs Market: 300841 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 300841 volatility | |
|---|---|
| 300841 Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300841 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300841's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 700 | Hongbo Wu | www.kangh.com |
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines.
Chengdu Kanghua Biological Products Co., Ltd. Fundamentals Summary
| 300841 fundamental statistics | |
|---|---|
| Market cap | CN¥7.55b |
| Earnings (TTM) | CN¥546.18m |
| Revenue (TTM) | CN¥1.65b |
13.8x
P/E Ratio4.6x
P/S RatioIs 300841 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300841 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.65b |
| Cost of Revenue | CN¥100.77m |
| Gross Profit | CN¥1.55b |
| Other Expenses | CN¥1.00b |
| Earnings | CN¥546.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.20 |
| Gross Margin | 93.88% |
| Net Profit Margin | 33.15% |
| Debt/Equity Ratio | 6.3% |
How did 300841 perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yield49%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 05:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chengdu Kanghua Biological Products Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yizhang Zhu | Citic Securities Co., Ltd. |
| Zhu Chen | Citic Securities Co., Ltd. |
| Mingrui Wang | Everbright Securities Co. Ltd. |